PubRank

Peter D Kwong

Author PubWeight™ 281.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antibody neutralization and escape by HIV-1. Nature 2003 21.48
2 Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010 14.91
3 Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007 11.73
4 Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010 10.69
5 HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004 9.48
6 Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011 7.92
7 Structure of a V3-containing HIV-1 gp120 core. Science 2005 7.69
8 Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011 7.20
9 The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002 6.11
10 Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012 5.44
11 Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013 5.35
12 Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004 5.29
13 Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A 2004 5.15
14 Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013 4.82
15 Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005 4.68
16 Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003 4.49
17 Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007 4.35
18 Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009 4.20
19 Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011 4.06
20 Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A 2009 3.92
21 Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013 3.90
22 Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012 3.83
23 Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010 3.40
24 Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013 3.04
25 Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 2003 3.03
26 Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013 2.95
27 Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002 2.91
28 Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 2002 2.81
29 Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008 2.74
30 Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A 2012 2.69
31 Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 2010 2.68
32 Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 2011 2.53
33 Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 2013 2.48
34 Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 2013 2.42
35 Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003 2.25
36 Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 2010 2.22
37 Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol 2007 2.19
38 Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 2011 2.17
39 Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013 2.17
40 The rational design of an AIDS vaccine. Cell 2006 2.11
41 Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 2005 2.09
42 Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 2009 2.07
43 Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 2003 1.90
44 Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 2010 1.89
45 Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol 2009 1.88
46 Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 2012 1.86
47 Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol 2010 1.70
48 Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2009 1.70
49 Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol 2010 1.62
50 Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 2012 1.61
51 PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol 2012 1.58
52 A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 2012 1.54
53 Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci U S A 2013 1.51
54 Enhancing protein crystallization through precipitant synergy. Structure 2003 1.51
55 Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 2008 1.44
56 Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability. J Virol 2011 1.43
57 A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J Virol 2010 1.43
58 Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J Virol 2005 1.42
59 Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 2011 1.41
60 Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol 2011 1.39
61 Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol 2010 1.38
62 Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J Virol 2011 1.38
63 Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol 2008 1.32
64 Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 2011 1.29
65 Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J Med Chem 2012 1.29
66 Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci 2011 1.28
67 Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol 2011 1.26
68 Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J Virol 2009 1.26
69 Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics. Front Microbiol 2012 1.24
70 Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol 2009 1.23
71 Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J Mol Biol 2010 1.22
72 Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle. J Virol 2012 1.21
73 Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat Chem Biol 2013 1.17
74 Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J Virol Methods 2010 1.17
75 Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One 2011 1.15
76 Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. J Mol Biol 2008 1.14
77 Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. J Virol 2010 1.11
78 Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J Virol 2013 1.10
79 N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. PLoS One 2013 1.09
80 Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus. J Med Chem 2007 1.08
81 Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem 2010 1.06
82 De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proc Natl Acad Sci U S A 2013 1.06
83 Structural basis for norovirus inhibition and fucose mimicry by citrate. J Virol 2011 1.05
84 Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res 2014 1.04
85 Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. J Virol 2012 1.03
86 Computational prediction of N-linked glycosylation incorporating structural properties and patterns. Bioinformatics 2012 1.03
87 Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem 2012 1.02
88 Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. Structure 2013 1.00
89 Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. J Virol 2007 0.97
90 Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry. Bioorg Med Chem 2008 0.96
91 Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 2011 0.96
92 Transplanting supersites of HIV-1 vulnerability. PLoS One 2014 0.96
93 Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. J Med Chem 2013 0.95
94 Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. ACS Chem Biol 2011 0.94
95 Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding. J Virol 2012 0.92
96 Human immunodeficiency virus: refolding the envelope. Nature 2005 0.92
97 Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol 2015 0.91
98 Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol 2013 0.91
99 Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol 2012 0.90
100 Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J Biol Chem 2012 0.89
101 Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262. Proteins 2015 0.89
102 Interfacial metal and antibody recognition. Proc Natl Acad Sci U S A 2005 0.88
103 HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Expert Opin Ther Targets 2015 0.86
104 Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Curr Opin HIV AIDS 2013 0.85
105 The 447-52D antibody: hitting HIV-1 where its armor is thickest. Structure 2004 0.85
106 Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. J Virol 2013 0.80
107 Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy. J Biomol NMR 2011 0.77
108 Mammalian expression of isotopically labeled proteins for NMR spectroscopy. Adv Exp Med Biol 2012 0.76
109 V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1. J Acquir Immune Defic Syndr 2016 0.75
110 Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathog 2016 0.75
111 How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Curr Opin HIV AIDS 2017 0.75
112 How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Curr Opin HIV AIDS 2017 0.75
113 Corrigendum: Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. Nat Struct Mol Biol 2017 0.75
114 Correction to Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. J Med Chem 2017 0.75